Perspective Therapeutics, Inc.
Financials
Valuation Metrics
Perspective Therapeutics, Inc.'s Market Cap is $327M. At end of 2025 it was $203M. Ranked #2925 of 3,121 in US market (top 94%), #1610 of 1,658 on NYSE (top 97%), #184 of 205 in Health Care Equipment & Services (top 90%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $327M | US#2,925/3,121 Sec#184/205 |
| Revenue | $366000.00 | US#2,882/3,121 Sec#200/205 |
| Net Income | $-116M | US—/3,121 Sec—/205 |
| Total Assets | $392M | US#2,852/3,121 Sec#166/205 |
| Net Assets | $324M | US#2,490/3,121 Sec#141/205 |
| Employees | 165 | US#2,528/3,121 Sec#175/205 |
| Value | ||
| P/B | 1.01x | US#388/3,121 Sec#20/205 |
| P/S | 894.30x | US#2,988/3,121 Sec#203/205 |
| FCF Yield | -37.02% | US—/3,121 Sec—/205 |
| Profitability | ||
| ROE | -35.95% | US#2,605/3,121 Sec#160/205 |
| ROA | -29.70% | US#2,880/3,121 Sec#187/205 |
| Op. Margin | -34216.39% | US#2,883/3,121 Sec#200/205 |
| Financial Health | ||
| Debt Ratio | 21.05% | US#239/3,121 Sec#23/205 |
| Total Debt | $4M | US#2,927/3,121 Sec#196/205 |
| FCF | $-121M | US#2,676/3,121 Sec#192/205 |
| Cash | $48M | US#2,587/3,121 Sec#165/205 |
| Current Ratio | 6.61x | US#374/3,121 Sec#24/205 |
| Performance | ||
| 1Y Return | -12.77% | US#1,982/3,121 Sec#137/205 |
| 1M Return | -17.53% | US#2,462/3,121 Sec#169/205 |
| From 52W High | -53.41% | US#2,801/3,121 Sec#183/205 |
| 1Y MDD | -58.84% | US#2,752/3,121 Sec#169/205 |
| Trading | ||
| Volume | 11,529,938 shares | US#1,365/3,121 Sec#84/205 |
| Trading Value | $33M | US#2,819/3,121 Sec#177/205 |
| Per Share | ||
| EPS | $-1.02 | US—/3,121 Sec—/205 |
| BPS | $2.84 | US#2,509/3,121 Sec#165/205 |
Company Info
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.